Surveillance colonoscopy and biopsy are inaccurate methods of predicting the likelihood of ulcerative colitis patients to develop colon carcinoma. We examined uPA and PAI-1 as potential markers for assessing these patients and those with familial polyposis who are at risk of developing colon cancer.
Topological localization of plasminogen activator inhibitor type 2
β Scribed by Michael A. Liew; Virginia McPhun; Mark S. Baker
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 281 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0196-4763
No coin nor oath required. For personal study only.
β¦ Synopsis
Background: Plasminogen activator inhibitor type 2 (PAI-2) is a member of the serine protease inhibitor (SER-PIN) superfamily and forms stable complexes with urokinase type plasminogen activator (uPA). uPA can be found on the cell surface attached to its specific receptor (uPAR), allowing for controlled degradation of the extracellular matrix by the activation of plasminogen into plasmin. The aim of this study was to evaluate if PAI-2 could also be detected on the cell surface, providing a means of regulating the activity of cell surface uPA. Methods: Intact or permeabilized cell lines or human peripheral blood leukocytes were assayed by flow cytometry for cell surface uPA or PAI-2. Plasma membraneenriched preparations prepared from Jurkat, HaCaT, THP-1, U937, or MM6 cells were assayed by enzyme-linked immunosorbent assay (ELISA) or Western blotting for PAI-2 antigen. Results: By flow cytometry, cell surface PAI-2 was not detected on monocytes from human peripheral blood, MM6, or HaCaT cells. Cell surface PAI-2 was only detected very weakly on the surface of U937 cells. In contrast, PAI-2 could be detected in all of these cells when fixed and permeabilized. By ELISA, PAI-2 was very abundant in the cytosol-enriched preparations of U937, MM6, and Ha-CaT cells, but was present in lower amounts in the plasma membrane-enriched preparations. By Western blotting, monomeric nonglycosylated PAI-2, but not uPA/PAI-2 complexes, could be detected in the cytosol and plasma membrane-enriched preparations. Conclusions: These results indicate that PAI-2 cannot be detected on the surface of PAI-2-expressing cells, and confirm that PAI-2 is predominantly a cytosolic protein.
π SIMILAR VOLUMES
We used an immunohistochemical assay with an antigenretrieval technique to study plasminogen activator inhibitor type-I (PAL I) expression in paraffin-embedded breast tissue samples at different stages of malignant transformation. We detected PAI-I in 15/20 invasive tumors. In several cases staining
The purpose was to characterize plasminogen activator inhibitor type 2 (PAI-2) expression in normal human conjunctiva in vivo and in vitro. PAI-2 antigen was assayed by immunostaining and immunoblotting of extracts from normal human conjunctival epithelial lysates and conditioned media (CM) of cultu
In experimental models, plasminogen activator-mediated degradation of the extracellular matrix is inhibited by type-1 plasminogen activator inhibitor (PAI-1). PA14 has also been shown to protect tumour stromal tissue from autoproteolytic activities and may thus substantially promote tumour growth an